1. Search Result
Search Result
Results for "

M2/M1 macrophage ratio

" in MedChemExpress (MCE) Product Catalog:

1592

Inhibitors & Agonists

5

Screening Libraries

52

Fluorescent Dyes

69

Biochemical Assay Reagents

94

Peptides

4

MCE Kits

96

Inhibitory Antibodies

379

Natural
Products

106

Recombinant Proteins

41

Isotope-Labeled Compounds

43

Antibodies

7

Click Chemistry

62

Oligonucleotides

3

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y0520
    Itaconic acid
    2 Publications Verification

    Methylenesuccinic acid

    Endogenous Metabolite Ferroptosis Inflammation/Immunology Cancer
    Itaconic acid, a precursor of polymers, chemicals, and fuels, can be synthesized by many fungi. Itaconic acid also is a macrophage-specific metabolite. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. Itaconic acid has anti-inflammatory, anti-microbial and immunomodulatory effect .
    Itaconic acid
  • HY-125527
    Resolvin D1
    1 Publications Verification

    RvD1

    Endogenous Metabolite Inflammation/Immunology
    Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages .
    Resolvin D1
  • HY-N0577
    Apiin
    1 Publications Verification

    Apigenin 7-O-apiosylglucoside; Apigenin 7-(2-O-apiosylglucoside)

    NO Synthase Inflammation/Immunology
    Apiin is a flavonoid glycoside-based iNOS inhibitor. Apiin inhibits the expression of inducible nitric oxide synthase in activated macrophages. Apiin exhibits anti-inflammatory activity .
    Apiin
  • HY-136979
    RBN012759
    10+ Cited Publications

    PARP Inflammation/Immunology Cancer
    RBN012759 is a potent, selective and orally active inhibitor of PARP14, with an IC50 of <3 nM. RBN012759 displays 300-fold selectivity over the monoPARPs and 1000-fold selectivity over the polyPARPs. RBN012759 decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants .
    RBN012759
  • HY-128525

    Bacterial Reactive Oxygen Species (ROS) Infection Inflammation/Immunology
    Enterobactin is a siderophore produced by Gram-negative bacteria and has an extremely high affinity for iron. During the process of Salmonella typhimurium infecting macrophages, Enterobactin can not only help bacteria uptake iron but also reduce the antibacterial activity of macrophages. In addition, Enterobactin is also involved in the oxidative stress response of Escherichia coli. Enterobactin can be hydrolyzed by Fes in the cell and exert antioxidant effects by scavenging free radicals .
    Enterobactin
  • HY-P4855
    CRAMP (mouse)
    1 Publications Verification

    Bacterial TNF Receptor Infection Inflammation/Immunology
    CRAMP (mouse) is an antibacterial peptide and a functional homolog of LL-37 . CRAMP (mouse) exhibits potent antibacterial activity against Gram-negative bacteria . The complex formed by CRAMP (mouse) and CpG can activate macrophages to secrete TNF-α . CRAMP (mouse) plays a key role in wound healing, immune regulation and maintenance of intestinal homeostasis .
    CRAMP (mouse)
  • HY-152830

    Q702

    c-Fms TAM Receptor MHC Cancer
    Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
    Adrixetinib
  • HY-161949
    AP-6
    1 Publications Verification

    Potassium Channel Neurological Disease
    AP-6 is a selective inhibitor of TMEM175 with activity in modulating lysosomal function. Acute inhibition of TMEM175 by AP-6 increases lysosomal macromolecular catabolism, thereby accelerating macrophage and other digestive processes. AP-6 may be used in Parkinson's disease research .
    AP-6
  • HY-P990045

    ALE.F02

    Claudin Endocrinology
    Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1 monoclonal antibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .
    Lixudebart
  • HY-148591

    Epigenetic Reader Domain Inflammation/Immunology
    GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the production of CD206 + regulatory macrophages by inhibiting SP140 .
    GSK761
  • HY-P99273

    TNF Receptor Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
    Vorsetuzumab
  • HY-P990651

    TREM receptor Cancer
    PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8 + T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors .
    PY314
  • HY-148117

    PROTACs Macrophage migration inhibitory factor (MIF) Cancer
    MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. MD13 can be used for cancer research .
    MD13
  • HY-P99136
    Anti-Mouse IFN gamma Antibody (H22)
    1 Publications Verification

    IFNAR Infection Inflammation/Immunology
    Anti-Mouse IFN gamma Antibody (H22) is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IFN gamma Antibody (H22) abrogates specific binding of I25II-rIFN-γ to macrophages. Anti-Mouse IFN gamma Antibody (H22) inhibits macrophage-activating factor (MAF) (ID50 = 56 ng). Anti-Mouse IFN gamma Antibody (H22) inhibits IFN-gamma dependent antiviral activity (ID50 = 2 ng). Anti-Mouse IFN gamma Antibody (H22) neutralizes IFNγ in mice. Anti-Mouse IFN gamma Antibody (H22) can be used for the researches of inflammation and infection, such as arthritis .
    Anti-Mouse IFN gamma Antibody (H22)
  • HY-176293

    Prostaglandin Receptor Amyloid-β Neurological Disease
    EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC50: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases .
    EP2 receptor antagonist-3
  • HY-156174

    Toll-like Receptor (TLR) ADC Payload Cancer
    E104 (compound 1) is a potent and selective TLR7 agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs .
    E104
  • HY-P99704

    OCS-02

    TNF Receptor Inflammation/Immunology
    Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
    Licaminlimab
  • HY-113481

    Transmembrane Glycoprotein COX PKA Prostaglandin Receptor Inflammation/Immunology Cancer
    Prostaglandin E3 is an eicosanoid derived from eicosapentaenoic acid. Prostaglandin E3 inhibits polarization towards M1 but promotes polarization of M2a macrophages. Prostaglandin E3 shows anti-inflammatory and anti-tumor activity .
    Prostaglandin E3
  • HY-125531

    Others Others
    Dactylorhin A, a succinate derivative ester, is isolated from rhizomes of Gymnadenia conopsea. Dactylorhin A exhibits moderate inhibitory effects on NO production effects in RAW 264.7 macrophage cells .
    Dactylorhin A
  • HY-135517

    RXP-470

    MMP Cardiovascular Disease
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
    RXP470.1
  • HY-148775B

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) has a molecular weight of 20kDA to 5.0kDA and contains a 40:60 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)
  • HY-P10586A

    MALP-2 TFA

    Toll-like Receptor (TLR) NO Synthase Cardiovascular Disease Metabolic Disease
    Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
    Macrophage-activating lipopeptide 2 TFA
  • HY-P11107

    Apoptosis TNF Receptor Inflammation/Immunology Cancer
    RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF) .
    RP-832c
  • HY-175613

    FAP Cancer
    DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers .
    DOTA-ALB-02
  • HY-117432

    NOD-like Receptor (NLR) Inflammation/Immunology
    JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages .
    JC-171
  • HY-P10420

    CD47 Interleukin Related Cancer
    RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
    RS17
  • HY-148776

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)
  • HY-168539

    HuR Inflammation/Immunology
    TM11, a Tanshinone mimic, is a potent HuR inhibitor that can inhibit HuR-RNA complex formation. TM11 reduces LPS-induced inflammatory response in murine macrophages .
    TM11
  • HY-148775

    Biochemical Assay Reagents Others
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .
    PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)
  • HY-P10586

    MALP-2

    Toll-like Receptor (TLR) NO Synthase Cardiovascular Disease
    Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .
    Macrophage-activating lipopeptide 2
  • HY-154928

    LXR Metabolic Disease
    GW6340 is an intestinal-specific LXR agonist. GW6340 promotes macrophage reverse cholesterol transport (mRCT) .
    GW6340
  • HY-139990
    CSF1R-IN-3
    1 Publications Verification

    c-Fms Cancer
    CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .
    CSF1R-IN-3
  • HY-163642

    Others Cancer
    TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .
    TNF-α agonistic 1
  • HY-W201317

    PPAR Metabolic Disease
    E17241 is an inducer of the expression of ABCA1 that increases the protein levels of ABCA1 in RAW 264.7 macrophages. E17241 is also an agonist of peroxisome proliferator-activated receptors (PPARs ). E17241 decreases plasma glucose levels and body weight in KKAy diabetic mice fed a high-fat and high-glucose (HFHG) diet .
    E17241
  • HY-B2150

    4-Hydroxyphenazone; NSC 174055

    Drug Metabolite Others
    4-Hydroxyantipyrine (4-Hydroxyphenazone; NSC 174055) is the major metabolite of Antipyrine (HY-B0171), can be as a biodistribution promoter. 4-Hydroxyantipyrine can increase distribution of concentration ratio of Citicoline and Antipyrine in the brain .
    4-Hydroxyantipyrine
  • HY-149218

    Thyroid Hormone Receptor Metabolic Disease Inflammation/Immunology
    THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC50s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research .
    THR-β agonist 6
  • HY-P991181

    Transmembrane Glycoprotein Cancer
    VTX-1218 is a VSIG4 inhibitor with human Kd 7.4 nM. VTX-1218 blocks VSIG4 activity, relieves VSIG4-mediated macrophage suppression, repolarizes tumor-associated macrophages and induces T cell activation. VTX-1218 upregulates cytokines and chemokines linked to immune cell recruitment. VTX-1218 can be used for the research of multiple cancer types .
    VTX-1218
  • HY-124122

    VEGFR Checkpoint Kinase (Chk) Apoptosis Caspase Bcl-2 Family Cancer
    BPTQ is a potent inhibitor against VEGFR1 and CHK2 with IC50 values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC50 value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases .
    BPTQ
  • HY-156177

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 16 (compound 16d) is a highly potent TLR7 agonist with an EC50 of 18 nM. TLR7 agonist 16 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .
    TLR7 agonist 16
  • HY-156176

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 15 (compound 16b) is a highly potent TLR7 agonist with an EC50 of 18 nM. TLR7 agonist 15 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .
    TLR7 agonist 15
  • HY-108644

    p38 MAPK Inflammation/Immunology
    SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) .
    SB 706504
  • HY-144041

    c-Fms Cancer
    CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .
    CSF1R-IN-5
  • HY-144190

    Macrophage migration inhibitory factor (MIF) Neurological Disease
    MIF-IN-1 (compound 14) is a potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=6.87) .
    MIF-IN-1
  • HY-157469

    NPD3064

    HIV Infection
    TNT-i (NPD3064) is an inhibitor targeting M-Sec. TNT-i inhibits M-Sec-induced tunneling nanotube (TNT) formation reversibly. TNT-i reduces wild-type HIV-1 production in macrophages and M-Sec-expressing T cells. TNT-i shows low cytotoxic effects on macrophages and T cells. TNT-i can be used for the research of HIV-1 infection .
    TNT-i
  • HY-P990061

    JTX 8064

    LILRB Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
    Polzastobart
  • HY-N12283

    NF-κB Inflammation/Immunology
    NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects .
    NF-κB-IN-13
  • HY-124814

    Bacterial Infection
    C215 is a potent inhibitor of MmpL3. C215 is identified in HTS with glycerol independent activity against M. tuberculosis, limited non-specific toxicity against mammalian cells, an IC90 of 16 μM against M. tuberculosis, and efficacy against M. tuberculosis growing in macrophages .
    C215
  • HY-D1257

    Msr-green

    Fluorescent Dye Others
    Msr-Ratio (Msr-green) is a ratiometric fluorescent probe of methionine sulfoxide reductase (λex=375 nm, λem=550 nm). Msr-Ratio is used for monitoring the enzyme activity in vitro and in live cells .
    Msr-Ratio
  • HY-163971

    Biochemical Assay Reagents Others
    Granulocyte-macrophage colony-stimulating factor is a biochemical assay reagent.
    Granulocyte-macrophage colony-stimulating factor
  • HY-158264

    Serotonin Transporter Endocrinology
    SNRI-IN-1 (Compound 7a) is a dual serotonin and noradrenaline monoamine reuptake inhibitor, P-glycoprotein Efflux Ratio is 20 .
    SNRI-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: